For the quarter ending 2026-03-31, RCUS has $997M in assets. $201M in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 201 | 222 | 238 | 248 |
| Marketable securities | 621 | 759 | 593 | 663 |
| Receivable from collaboration partners | 3 | 11 | 11 | 15 |
| Prepaid expenses and other current assets | 19 | 15 | 15 | 20 |
| Total current assets | 844 | 1,007 | 857 | 946 |
| Long-term marketable securities | 54 | 29 | 10 | 16 |
| Property and equipment, net | 38 | 40 | 42 | 44 |
| Other noncurrent assets | 61 | 63 | 65 | 69 |
| Total assets | 997 | 1,139 | 974 | 1,075 |
| Accounts payable (11 and 24 to a related party) | 39 | 42 | 42 | 29 |
| Deferred revenue (27 and 35 to a related party) | 34 | 35 | 52 | 71 |
| Other current liabilities | 136 | 154 | 141 | 110 |
| Total current liabilities | 209 | 231 | 235 | 210 |
| Deferred revenue, noncurrent (36 and 43 to a related party) | 45 | 43 | 53 | 60 |
| Long-term debt | 100 | 99 | 98 | 97 |
| Other noncurrent liabilities | 119 | 135 | 152 | 159 |
| Common stock and additional paid-in capital 0.0001 par value per share 400.0 shares authorized 125.5 shares in 2026 and 125.3 shares in 2025 issued and outstanding | 2,138 | 2,116 | 1,815 | 1,793 |
| Accumulated deficit | -1,613 | -1,485 | -1,379 | -1,244 |
| Accumulated other comprehensive loss | -1 | - | - | - |
| Total stockholders equity | 524 | 631 | 436 | 549 |
| Total liabilities and stockholders equity | 997 | 1,139 | 974 | 1,075 |
Arcus Biosciences, Inc. (RCUS)
Arcus Biosciences, Inc. (RCUS)